Biomarker | Â | Normal Control (n = 244) | Benign (n = 223) | Borderline (n = 53) | Early Stage Malignant (Stages I & II) (n = 69) | Late Stage Malignant (Stages III & IV) (n = 120) |
---|---|---|---|---|---|---|
CA-125 | Mean ± SE | 6.05 ± 10.4 | 27.35 ± 10.2 | 180.3 ± 137 | 380.9 ± 97 | 1337.0 ± 420 |
(U/mL) | Median (range) | 4.10 (0.5-146)a | 7.60 (0.5-2219)a | 13.1 (1.2-7266)a, b | 52.3 (0.5-4277)a, b | 208.5 (3.3-47206)a, b |
CRP | Mean ± SE | 3.99 ± 0.7 | 8.20 ± 1.5 | 10.05 ± 3.6 | 16.73 ± 3.4 | 39.65 ± 4.5 |
(mg/L) | Median (range) | 1.38 (0.08-149.4) | 1.81 (0.08-172.7) | 3.09 (0.17-186.7) | 4.77 (0.10-139.1)a, b | 21.80 (0.30-309.5)a, b |
SAA | Mean ± SE | 10.82 ± 2.5 | 29.00 ± 7.9 | 22.11 ± 11.3 | 47.47 ± 13.3 | 127.7 ± 24.3 |
(mg/L) | Median (range) | 4.34 (0.77-489.0) | 4.95 (0.80-1337) | 4.74 (1.20-593.2) | 8.50 (1.00-737.0)a, b | 24.23 (0.96-1958)a, b |
IL-6 | Mean ± SE | 2.11 ± 0.23 | 2.61 ± 0.25 | 6.26 ± 2.79 | 8.54 ± 1.71 | 20.09 ± 6.29 |
(pg/ml) | Median (range) | 1.00 (1.00-38.50) | 1.00 (1.00-29.50) | 1.00 (1.00-146.0) | 4.10 (1.00-93.70)a, b | 8.45 (1.00-628.0)a, b |
IL-8 | Mean ± SE | 3.73 ± 0.33 | 10.27 ± 1.81 | 16.83 ± 5.67 | 19.27 ± 4.88 | 29.36 ± 5.88 |
(pg/mL) | Median (range) | 2.50 (2.50-58.70) | 2.50 (2.50-292.0)a | 2.50 (2.50-183.0)a | 2.50 (2.50-239.0)a, b | 6.10 (2.50-408.0)a, b |